REG - Imaging Biometrics - Release of Next-Generation IB Clinic

Imaging BiometricsAnnouncement

26/11/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251126:nRSZ1481Ja&default-theme=true

RNS Number : 1481J  Imaging Biometrics Limited  26 November 2025

Imaging Biometrics, Ltd

("IBAI" or the "Company")

 

Imaging Biometrics Announces Release of Next-Generation IB Clinic

 

Imaging Biometrics, LLC, ("IB"), a leader in advanced quantitative imaging
solutions, is pleased to announce the release of the next version of IB
Clinic, its comprehensive image processing suite featuring renowned products
such as IB Neuro, IB DCE, IB Rad Tech, and others. The release marks a
significant leap forward in automation, scalability, workflow integration and
customization across its imaging technologies.

 

This release delivers true hands-free, platform-independent functionality,
transforming IB's proven and quantitative imaging technologies into a fully
automated environment that saves time and reduces manual steps. By
consolidating nearly all IB plugin capabilities into one streamlined solution,
IB Clinic eliminates workflow bottlenecks, minimizes user intervention, and
ensures consistent, reproducible results with its exclusive standardization
technology. Clinicians can now focus on interpretation and patient care rather
than technical setup, while integrated third-party applications enable
seamless access to complementary tools-all within a single platform. This
level of automation and interoperability accelerates decision-making, improves
reporting efficiency, and supports collaboration across clinical, research,
and commercial settings.

 

Through IB's quantitative tools and fully customizable workflows, clinicians
and researchers can now access ROI-based volumetrics, longitudinal reporting
of Delta T1 and fractional tumor burden ("FTB") volumes, and standardized
DICOM SR storage within a single, integrated environment. Expanded imaging
capabilities-including ASL (arterial spin labeling), SAGE (spiral and gradient
echo) perfusion, DCE enhancements, and diffusion MRI processing-deliver
further insights, while user-centric features like color-blind support,
customizable lookup tables, and automated reporting streamline interpretation
and documentation. Combined with seamless integration across physical and
cloud-based platforms, IB Clinic empowers users to achieve faster, more
accurate results tailored to their unique clinical and research needs.

 

Behind the scenes, IB has implemented over 30 stability improvements and bug
fixes, expanded support for Mac viewer platforms, and modernized its
development pipeline with automated testing of parameter map generation. These
operational upgrades ensure that IB Clinic continues to deliver reliability
and scalability as adoption grows.

 

Timothy Dondlinger, COO of Imaging Biometrics, LLC, commented: "This release
of IB Clinic represents a pivotal step in our mission to make advanced
neuroimaging accessible, automated, and seamlessly integrated into diverse
workflows. By combining automation with flexibility, we are empowering
clinicians, researchers, and partners to accelerate discovery and improve
patient outcomes."

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 

 Imaging Biometrics Ltd

 Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X, @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFLFSSLALRFIE



            Copyright 2019 Regulatory News Service, all rights reserved